Document is current
Any future updates will be listed below
-
Authors
Liu, Yang
Wang, Chunmeng
Li, Xiang
Dong, Liang
Yang, Qingming
Chen, Meixia
Shi, Fengxia
Brock, Malcolm
Liu, Miao
Mei, Qian
Liu, Jiejie
Nie, Jing
Han, Weidong https://orcid.org/0000-0003-3207-3899
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02961101 at ClinicalTrials.govnct03250962 at ClinicalTrials.govDocuments that mention this clinical trial
Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
https://doi.org/10.1136/jcp-2024-209848
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
https://doi.org/10.1136/jitc-2021-002347
nct02684292 at ClinicalTrials.govDocuments that mention this clinical trial
Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
https://doi.org/10.1136/jcp-2024-209848
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
https://doi.org/10.1136/jitc-2021-002347
nct03138499 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
https://doi.org/10.1136/jitc-2021-002347
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
https://doi.org/10.1136/jitc-2021-002347
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (31870873)
National Natural Science Foundation of China (31991171)
National Natural Science Foundation of China (81803071)
National Natural Science Foundation of China (81830002)
National Natural Science Foundation of China (81872479)
National Natural Science Foundation of China (81903153)
National Natural Science Foundation of China (82022057)
Chinese PLA General Hospital’s National Excellent Young Scholar Science (2017-YQPY-2017, 2020-JQPY-001)
National Key Research and Development Program of China (2019YFC1316205 to JN)
- License Information
